SG11202002697WA - Modulating the immune response using antibody-drug conjugates - Google Patents
Modulating the immune response using antibody-drug conjugatesInfo
- Publication number
- SG11202002697WA SG11202002697WA SG11202002697WA SG11202002697WA SG11202002697WA SG 11202002697W A SG11202002697W A SG 11202002697WA SG 11202002697W A SG11202002697W A SG 11202002697WA SG 11202002697W A SG11202002697W A SG 11202002697WA SG 11202002697W A SG11202002697W A SG 11202002697WA
- Authority
- SG
- Singapore
- Prior art keywords
- modulating
- antibody
- immune response
- drug conjugates
- conjugates
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762572345P | 2017-10-13 | 2017-10-13 | |
| US201762576017P | 2017-10-23 | 2017-10-23 | |
| US201862657511P | 2018-04-13 | 2018-04-13 | |
| PCT/US2018/055388 WO2019075188A1 (fr) | 2017-10-13 | 2018-10-11 | Modulation de la réponse immunitaire à l'aide de conjugués anticorps-médicament |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002697WA true SG11202002697WA (en) | 2020-04-29 |
Family
ID=66101160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002697WA SG11202002697WA (en) | 2017-10-13 | 2018-10-11 | Modulating the immune response using antibody-drug conjugates |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20200239585A1 (fr) |
| EP (1) | EP3694544A4 (fr) |
| JP (2) | JP2020536932A (fr) |
| KR (1) | KR20200070317A (fr) |
| CN (2) | CN111683677A (fr) |
| AU (1) | AU2018348198A1 (fr) |
| BR (1) | BR112020007119A2 (fr) |
| CA (1) | CA3077729A1 (fr) |
| IL (1) | IL273720A (fr) |
| MA (1) | MA50369A (fr) |
| MX (1) | MX2020003460A (fr) |
| SG (1) | SG11202002697WA (fr) |
| TW (1) | TW201934142A (fr) |
| WO (1) | WO2019075188A1 (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022005240A (es) * | 2019-11-04 | 2022-08-19 | Seagen Inc | Conjugados de farmaco-anticuerpo anti-cd30 y su uso para el tratamiento de infeccion por vih. |
| JP7258224B2 (ja) * | 2020-03-16 | 2023-04-14 | 株式会社マンダム | Ｔ細胞性リンパ腫の指標の検出方法、及びその利用 |
| EP4149559A1 (fr) * | 2020-05-13 | 2023-03-22 | Seagen Inc. | Méthodes de traitement du cancer faisant appel à une association de conjugués anticorps anti-cd30-médicament |
| JP2023551894A (ja) * | 2020-12-03 | 2023-12-13 | シージェン インコーポレイテッド | 抗ｃｄ３０抗体－薬物コンジュゲートを使用した免疫応答の調節 |
| US12036286B2 (en) | 2021-03-18 | 2024-07-16 | Seagen Inc. | Selective drug release from internalized conjugates of biologically active compounds |
| CA3226977A1 (fr) * | 2021-08-25 | 2023-03-02 | R.P. Scherer Technologies, Llc | Anticorps ayant des regions charpentes humanisees |
| KR20240099363A (ko) | 2021-10-29 | 2024-06-28 | 씨젠 인크. | 항-pd-1 항체와 항-cd30 항체-약물 접합체의 조합을 사용하여 암을 치료하는 방법 |
| IL315178A (en) * | 2022-02-28 | 2024-10-01 | Adc Therapeutics Sa | Dosage regimen |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002363939A1 (en) * | 2001-11-20 | 2003-06-10 | Seattle Genetics, Inc. | Treatment of immunological disorders using anti-cd30 antibodies |
| WO2008025020A2 (fr) * | 2006-08-25 | 2008-02-28 | Seattle Genetics, Inc. | agents de liaison de CD30 et leurs usages |
| CN101969970B (zh) * | 2007-10-12 | 2014-10-15 | 西雅图基因公司 | 用抗体-药物偶联物联合治疗 |
| CA3051090C (fr) * | 2009-01-09 | 2022-04-12 | Seattle Genetics, Inc. | Regimes posologiques hebdomadaires pour des conjugues anticorps anti-cd30 vc-pab-mmae - medicament |
| WO2015037000A1 (fr) * | 2013-09-11 | 2015-03-19 | Compugen Ltd | Polypeptides vstm5 et leurs utilisations en tant que médicament pour le traitement du cancer, de maladies infectieuses et de maladies de type immunitaire |
| FI3464368T3 (fi) * | 2016-06-02 | 2023-09-12 | Bristol Myers Squibb Co | Anti-pd-1-vasta-aineen käyttö yhdistelmänä anti-cd30-vasta-aineen kanssa lymfooman hoitamisessa |
| WO2018112032A1 (fr) * | 2016-12-13 | 2018-06-21 | President And Fellows Of Harvard College | Procédés et compositions pour le ciblage de lymphocytes t régulateurs infiltrant les tumeurs |
-
2018
- 2018-10-11 MA MA050369A patent/MA50369A/fr unknown
- 2018-10-11 CN CN201880079374.3A patent/CN111683677A/zh active Pending
- 2018-10-11 WO PCT/US2018/055388 patent/WO2019075188A1/fr active Application Filing
- 2018-10-11 EP EP18865815.7A patent/EP3694544A4/fr active Pending
- 2018-10-11 JP JP2020520650A patent/JP2020536932A/ja active Pending
- 2018-10-11 SG SG11202002697WA patent/SG11202002697WA/en unknown
- 2018-10-11 US US16/755,091 patent/US20200239585A1/en not_active Abandoned
- 2018-10-11 CA CA3077729A patent/CA3077729A1/fr active Pending
- 2018-10-11 CN CN202410254365.0A patent/CN118356508A/zh active Pending
- 2018-10-11 AU AU2018348198A patent/AU2018348198A1/en active Pending
- 2018-10-11 BR BR112020007119-6A patent/BR112020007119A2/pt unknown
- 2018-10-11 KR KR1020207013530A patent/KR20200070317A/ko not_active Application Discontinuation
- 2018-10-11 MX MX2020003460A patent/MX2020003460A/es unknown
- 2018-10-12 TW TW107135971A patent/TW201934142A/zh unknown
-
2020
- 2020-03-31 IL IL273720A patent/IL273720A/en unknown
-
2022
- 2022-10-17 US US18/047,240 patent/US20230279133A1/en active Pending
-
2023
- 2023-11-10 JP JP2023191995A patent/JP2024016220A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20200070317A (ko) | 2020-06-17 |
| AU2018348198A1 (en) | 2020-04-23 |
| MA50369A (fr) | 2020-08-19 |
| JP2024016220A (ja) | 2024-02-06 |
| EP3694544A4 (fr) | 2021-08-11 |
| MX2020003460A (es) | 2020-08-03 |
| CN118356508A (zh) | 2024-07-19 |
| CN111683677A (zh) | 2020-09-18 |
| CA3077729A1 (fr) | 2019-04-18 |
| TW201934142A (zh) | 2019-09-01 |
| IL273720A (en) | 2020-05-31 |
| WO2019075188A1 (fr) | 2019-04-18 |
| US20230279133A1 (en) | 2023-09-07 |
| JP2020536932A (ja) | 2020-12-17 |
| EP3694544A1 (fr) | 2020-08-19 |
| US20200239585A1 (en) | 2020-07-30 |
| BR112020007119A2 (pt) | 2020-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201904269B (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| IL273720A (en) | Modulation of the immune response using antibody-drug conjugates | |
| SI3592393T1 (sl) | Sprostljivi konjugati | |
| PL3544636T3 (pl) | Koniugaty pirolobenzodiazepina-przeciwciało | |
| GB201702031D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| IL269945B (en) | Conjugates of pyrrolobenzodiazepine | |
| HK1257352A1 (zh) | 靶向gcc的抗體-藥物綴合物 | |
| SG11202101517PA (en) | Isoquinoline-steroid conjugates and uses thereof | |
| IL266112A (en) | Antibodies against edb and antibody-drug conjugates | |
| EP3538098A4 (fr) | Conjugués anticorps-médicament | |
| HK1258338A1 (zh) | 靶向uparap的抗體-藥物綴合物 | |
| GB201820864D0 (en) | Antibody-drug conjugates | |
| GB201820626D0 (en) | Conjugates | |
| GB201811332D0 (en) | Pyrroloobenzodiazepine-antibody conjugates | |
| GB201811335D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201721290D0 (en) | Conjugates | |
| GB201719906D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201719398D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201719393D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201719391D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201721337D0 (en) | Pyrrolobenzodiazepine conjugates | |
| GB201706466D0 (en) | pyrrolobenzodiazepine-peptide conjugates | |
| GB201702029D0 (en) | Pyrrolobenzodiazepine-antibody conjugates | |
| GB201706133D0 (en) | Pyrrolobenzodiazepine conjugates |